Results 91 to 100 of about 3,657 (192)

REVIEW ON DELAMANID: A NEW EMA APPROVED DRUG FOR MULTI-DRUG RESISTANT TUBERCULOSIS

, 2017
Tuberculosis is emerging globally with an estimated prevalence of 8.7 million cases annually and 1.4 million deaths. The disease is caused by Mycobacterium tuberculosis.
Gopika B , Keerthana Kripa R R , Renuka R *, Dr. Elessy Abraham
core   +1 more source

Chemical structure of clinically approved anti-TB drugs bedaquiline (1) and delamanid (2).

, 2019
Chemical structure of clinically approved anti-TB drugs bedaquiline (1) and delamanid (2).
Hassan H. Abdallah (1936783), Mahesh Attimarad (4353310), Anroop B. Nair (6796820), Subhrajyoti Bhandary (2617587), Sandeep Chandrashekharappa (4353304), Nagaraja Sreeharsha (6796823), Shinu Pottathil (6796829), Melendhran Pillay (480710), Mohamed A. Morsy (6796826), Rashmi Venugopala (6796832), Koleka Mlisana (72866), Fawzi M. Mahomoodally (6262904), Bandar E. Aldhubiab (4353307), Katharigatta Narayanaswamy Venugopala (6796817), Deepak Chopra (328612), Bharti Odhav (4353301)   +15 more
core   +1 more source

Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis

Pharmaceuticals
Mycobacterium tuberculosis infections continue to pose a significant global health challenge, particularly due to the rise of multidrug-resistant strains, random mycobacterial mutations, and the complications associated with short-term antibiotic ...
Ahmad Diab, Henry Dickerson, Othman Al Musaimi   +2 more
doaj   +1 more source

Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: A systematic review

, 2017
The new drugs delamanid and bedaquiline are increasingly used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). As evidence is lacking, the World Health Organization recommends their use under specific conditions ...
Rendon, Adrian, Dalcolmo, Margareth, Lia D’Ambrosio, Margareth Dalcolmo, D'Ambrosio, Lia, Marina Tadolini, Adrian Rendon, Migliori, Giovanni Battista, Rosella Centis, Susanna Esposito, Centis, Rosella, Tiberi, Simon, Simon Tiberi, Tadolini, Marina, Giovanni Battista Migliori, Esposito, Susanna   +15 more
core   +1 more source

Effectiveness of new antituberculosis drugs in the treatment of children and adolescents with chemoresistant tuberculosis

Infusion & Chemotherapy
BACKGROUND. There is a significant decrease the effectiveness of antituberculous (anti-TB) treatment on the background of multidrug and extensive drug resistance (MDR/XDR) of Mycobacterium tuberculosis.
M.І. Sakhelashvili, I.L. Рlatonova, O.I. Sakhelashvili-Вil   +2 more
doaj   +1 more source

Hepatic Safety of Bedaquiline, Delamanid, and Pretomanid: A Systematic Review and Meta-analysis

International Journal of Mycobacteriology
Novel anti-tuberculosis (TB) drugs have been shown to effectively treat drug-resistant TB (DR-TB). However, there is a risk of hepatotoxicity. We aimed to evaluate the incidence of hepatotoxicity in TB patients receiving bedaquiline (BDQ), delamanid (DLM)
Mohamad Faisal Said Al Omar, Izz Eddin Majed Alchikhsuliman, Sondos Mahmoud Awad, Numa Rajab, Yousef Mohammed Alawi, Leena Yousif Mohamed Ibrahim, Idris Sula, Muhammad Candragupta Jihwaprani, Nazmus Saquib   +8 more
doaj   +1 more source

Bedaquiline plus delamanid for XDR tuberculosis [PDF]

The Lancet Infectious Diseases, 2016
Marie, Lachâtre, Christophe, Rioux, Damien, Le Dû, Mathilde, Fréchet-Jachym, Nicolas, Veziris, Elisabeth, Bouvet, Yazdan, Yazdanpanah   +6 more
openaire   +2 more sources

Outcomes in patients with multidrug- or rifampin-resistant tuberculosis treated with bedaquiline and/or delamanid under the South Korean nationwide approval process. [PDF]

BMC Infect Dis
Hwang H, Shin JE, Seo S, Hong SJ, Jang MR, Kang H, Mok J, Kwon YS, Jeon D, Shim TS, Yim JJ.   +10 more
europepmc   +1 more source

Cost-effectiveness evaluation of bedaquiline- and delamanid-containing regimens for multidrug-/rifampicin-resistant tuberculosis in China: a retrospective study based on three nationwide, real-world multicenter cohorts. [PDF]

J Thorac Dis
Sun D, Li Z, Qiu Y, Shu W, Zhang L, Gao J, Liu Y.   +6 more
europepmc   +1 more source

Rare emergence of delamanid resistance in multidrug-/rifampicin-resistant tuberculosis patients receiving delamanid-containing regimens: a prospective multicentric study in China. [PDF]

Ann Clin Microbiol Antimicrob
Shu W, Cai Q, Huang Y, Xu Y, Shang Y, Liang R, Yan L, Wang L, Jin L, Pei Y, Huang Z, Li S, Wang Y, Gao M, Li L, Pang Y.   +15 more
europepmc   +1 more source